Robert Pariser is a Dermatology physician affiliated with Old Dominion University. OpenAlex indexes 65 publications with 1,615 citations (h-index 21); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
6160 Kempsville Cir Ste 200a
Norfolk, VA 235023945
Telephone
757-622-6315Provider last certified this registry record 24 Jun 2024.
Clinical trials
- A Study of Adalimumab to Treat Sarcoidosis of the Skin
Sponsor: Pariser, Robert J., M.D.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
19 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year202511 payments
- Janssen Biotech, Inc.Program year20252 payments
- Galderma Laboratories, L.P.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
28%Corticosteroid28%Clobetasol Propionate46%Hydrocortisone29%Betamethasone Dipropionate11%Betamethasone Valerate8%Desonide3%Alclometasone Dipropionate3%Part D≥160 patientsDermatology
25.2%Corticosteroid16.8%Triamcinolone Acetonide100%Part D≥218 patientsInterleukin-4 Receptor alpha Antagonist3.5%Dupixent Pen100%Part D≥13 patients+ 6 more classes in this area
Anti-infectives
20.8%Azole Antifungal11.5%Ketoconazole100%Part D≥127 patientsTetracycline-class Drug5.4%Doxycycline Monohydrate52%Doxycycline Hyclate35%Minocycline Hcl13%Part D<11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- YouTube as a source of information for self-skin examinations: an analysis of content and quality
Clinical and Experimental Dermatology
2024 - Diagnostic Accuracy of <i>Treponema pallidum</i> Immunostaining in a Cohort of Patients With Secondary Syphilis
Journal of Cutaneous Pathology
2024 - Double-Blind, Placebo-Controlled Study of Onabotulinumtoxin A for the Treatment of Hailey-Hailey Disease
Journal of Drugs in Dermatology
2023
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”